Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

NCT02744209 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02744209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02744209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Terminated
Start date
April 30, 2016
Completion date
January 31, 2019
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv melanoma